KIT and acral lentiginous melanoma: In a systematic review by Steeb et al., which included studies investigating c-KIT inhibitor targeted therapy agents such as imatinib, nilotinib, and dasatinib, found an ORR of 22% (based on eight studies, n = 109 patients with ALM), a median PFS of 2.8 months (based on one study, n = 21 patients with ALM), and median OS of 21.1 months (based on one study, n = 21 patients with ALM) for patients with ALM.